HROW
Harrow Health, Inc. · Healthcare · Drug Manufacturers - Specialty & Generic
Momentum inputs (comparable managers):
holder breadth +11.1% ·
share flow +10.7% ·
net new positions +10.0%
· formula
Broad accumulation: rising shares across more holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q1 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 1 | 0 | 7.50K | $231,062 | n/a | n/a |
| Q2 2026 | 80 | +1 | 11.44M | $485.62M | +8 | −8 |
| Q1 2026 | 83 | -4 | 11.18M | $394.57M | +6 | −10 |
| Q4 2025 | 87 | 0 | 11.51M | $563.95M | +1 | −1 |
| Q3 2025 | 15 | -1 | 7.56M | $364.09M | +1 | −2 |
| Q2 2025 | 13 | 0 | 7.79M | $237.82M | n/a | n/a |
| Q1 2025 | 10 | +1 | 3.25M | $86.47M | +1 | n/a |
| Q4 2024 | 9 | 0 | 2.94M | $98.57M | n/a | n/a |
| Q3 2024 | 8 | +1 | 2.10M | $94.28M | +2 | −1 |
| Q2 2024 | 7 | n/a | 1.47M | $30.78M | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | State Street Global Advisors ✦ (passive) | 786.48K | -5.0% | $20.92M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 2 | Geode Capital Management ✦ (passive) | 774.08K | +7.3% | $20.60M | 0.0% | ▲ Add | 4 | SEC ↗ ×2 |
| 3 | D. E. Shaw & Co. ✦ | 468.19K | -29.6% | $12.45M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 4 | Marshall Wace ✦ | 429.67K | New | $11.43M | 0.0% | New | 1 | SEC ↗ ×2 |
| 5 | Citadel Advisors ✦ | 274.24K | +131.2% | $7.29M | 0.0% | ▲ Add | 4 | SEC ↗ ×2 |
| 6 | Renaissance Technologies ✦ | 245.37K | -11.6% | $6.53M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 7 | Two Sigma Investments ✦ | 101.41K | -32.5% | $2.70M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 8 | Millennium Management ✦ | 76.25K | +13.4% | $2.03M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 9 | Wellington Management ✦ | 74.74K | -18.1% | $1.99M | 0.0% | ▼ Trim | 4 | SEC ↗ ×2 |
| 10 | T. Rowe Price ✦ | 20.30K | +6.4% | $540,000 | 0.0% | ▲ Add | 4 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| Marshall Wace | $11.43M | 0.0% |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 216 holders, 21.37M shares, $751.67M reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer · 11.25K sh · $450,000
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology